Covaxx
Vaxxinity (formerly Covaxx) is a privately held biotech developing synthetic peptide-based vaccines and immunotherapies, led by the UB-612 COVID-19 booster that completed Phase III trials. It targets government health authorities and healthcare systems with a non-mRNA, cold-chain-independent platform.
- Company typePrivate
- Founded2019
- HeadquartersHauppauge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Covaxx firmographics
Firmographics- Name
- Covaxx
- Legal name
- Vaxxinity Inc.
- Website
- https://covaxx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Vaxxinity (formerly Covaxx) is a privately held biotech developing synthetic peptide-based vaccines and immunotherapies, led by the UB-612 COVID-19 booster that completed Phase III trials. It targets government health authorities and healthcare systems with a non-mRNA, cold-chain-independent platform.
- Ownership category
- akta.pro rank
Covaxx industry classification
Industry- Product category
- COVID-19 Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industry
- Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)
Keywords
Where Covaxx is headquartered
LocationHeadquarters
- HQ city
- Hauppauge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Covaxx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Vaccine Product Sales: Revenue generated from sale of COVID-19 vaccine products (UB-612) to governments, healthcare providers, and procurement programs. One-time vaccination course revenue model typical of pharmaceutical vaccine products.
- Clinical Development Partnerships: Partnership funding from organizations like CEPI to co-fund Phase III clinical trials, providing non-dilutive capital for vaccine development in exchange for future supply commitments.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Covaxx product offering
Product offeringCore offering
Covaxx (now operating as Vaxxinity) is a biotechnology company developing synthetic peptide-based vaccines, with its lead product being the UB-612 COVID-19 booster vaccine. The vaccine uses a non-mRNA, non-spike-protein approach that does not require frozen cold chain storage, enabling simpler and more cost-effective distribution. The company also maintains a computational pipeline for cross-reactive antibody discovery to support future vaccine and immunotherapy development.
Differentiator
Problem solved
Functional benefit
Products and services
- UB-612 COVID-19 Booster Vaccine A COVID-19 booster vaccine developed using a synthetic peptide-based platform rather than mRNA technology. It targets coronavirus antigens without using the spike protein, provides long-lasting protection against emerging variants, is well-tolerated, and remains stable at refrigerated (non-frozen) temperatures. Designed for governments, healthcare systems, and public vaccination programs seeking cost-effective, logistically simpler alternatives to mRNA vaccines.
Quantifiable outcome
- High success rate in predicting candidate cross-reactive antibodies for multiple coronavirus variants
- +1 more outcomes
Companies that use Covaxx
Customer profileSegments2 records
Ideal customer profiles2 records
Covaxx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Covaxx partnerships and signals
Strategic signalScale indicators3 records
Covaxx competitors and assessment
Company assessmentMarket position
Customer concentration
Covaxx social profiles
Digital presenceCovaxx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Covaxx leadership team
Management profileNumber of profiles
Profiles3 records
Covaxx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Covaxx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Covaxx
What does Covaxx do?
Covaxx (now operating as Vaxxinity) is a biotechnology company developing synthetic peptide-based vaccines, with its lead product being the UB-612 COVID-19 booster vaccine. The vaccine uses a non-mRNA, non-spike-protein approach that does not require frozen cold chain storage, enabling simpler and more cost-effective distribution. The company also maintains a computational pipeline for cross-reactive antibody discovery to support future vaccine and immunotherapy development.
Is Covaxx a public or private company?
Covaxx is a private company. It is classified as unknown and is currently operating.
When was Covaxx founded?
Covaxx was founded in 2019. It employs 51 to 100 people.
Where is Covaxx based?
Covaxx is headquartered in Hauppauge, United States, in the North America region.
How does Covaxx make money?
Two revenue lines are on record. Vaccine Product Sales are the primary driver. The others are clinical Development Partnerships.
Does Covaxx have an API?
No public API is recorded for Covaxx.
What industry is Covaxx in?
Covaxx's product category is COVID-19 Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2836.